Bruce Booth Sells 115,056 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 115,056 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56. Following the completion of the transaction, the director owned 647,914 shares of the company’s stock, valued at approximately $58,966,653.14. This represents a 15.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total transaction of $24,268,431.60.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.98, for a total transaction of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.96, for a total value of $530,764.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.10, for a total value of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.97, for a total transaction of $374,185.23.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $98.25 on Wednesday. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $105.00. The firm has a 50 day moving average price of $83.67 and a 200 day moving average price of $81.54. The company has a market capitalization of $8.08 billion, a PE ratio of -27.52 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the prior year, the firm earned ($0.82) earnings per share. The firm’s revenue was up 55.5% compared to the same quarter last year. As a group, equities research analysts forecast that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera’s last reported quarter beat expectations, with EPS of ($0.71) versus the ($0.89) consensus and revenue of $34.37 million versus $8.27 million, reinforcing confidence in the business outlook.
• Positive Sentiment: A Zacks note said KYMR shares surged in the prior session on above-average volume, with recent earnings-estimate revisions suggesting there may be additional upside near term. Article Title
• Neutral Sentiment: Several insider transactions were disclosed under pre-arranged Rule 10b5-1 plans, which often makes them less concerning as a signal about near-term fundamentals.
• Negative Sentiment: Director Bruce Booth sold multiple large blocks of shares, including a $24.3 million sale and additional recent sales, and insider Noah Goodman also sold shares. While these were planned transactions, the volume and frequency can weigh on sentiment. Article Title

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the fourth quarter valued at approximately $63,000. Osaic Holdings Inc. increased its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Kymera Therapeutics by 56.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after purchasing an additional 463 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Kymera Therapeutics in a research note on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price objective for the company. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Piper Sandler boosted their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Finally, Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.